BCD-132

Phase 2Biologic

BBiocad

BCD-132 is one of 61 biologic programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsing-Remitting Multiple SclerosisActive, not recruiting

Multiple SclerosisActive, not recruiting

Relapsing-Remitting Multiple SclerosisPhase 1

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Betaseron

Bayer

Preclinical

16 2

Kesimpta

Novartis

Preclinical

15 3

Tysabri

Biogen

Preclinical

14 4

Avonex

EMD Serono

Preclinical

22 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Pred Forte

Myfortic

Novantrone

BCD-132

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Sclerosis2 trials

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Completed·BBiocad·Phase 3·NCT05385744·336 enrolled

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Completed·BBiocad·Phase 2·NCT04056897·271 enrolled

Relapsing-Remitting Multiple Sclerosis1 trial

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Completed·BBiocad·Phase 1·NCT03551275·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BCD-132. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCD-132 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCD-132. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBiocad

BCD-132

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Sclerosis2 trials

Relapsing-Remitting Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News